Levetiracetam and Dyspnoea exacerbated for Women aged 40-49 (a phase IV clinical study of FDA data)

Summary:

Dyspnoea exacerbated is found for women aged 40-49 who take Levetiracetam (levetiracetam). This study is created by eHealthMe based on reports of 2,972 women aged 40-49 from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Levetiracetam when people have Dyspnoea exacerbated
Top conditions
Top co-used drugs
Top other side effects

On Jul, 29, 2026

2,972 women aged 40-49 reported to have side effects when taking Levetiracetam.
Among them, 53 people (1.78%) have Dyspnoea exacerbated

What is Levetiracetam?

Levetiracetam has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 75,292 Levetiracetam users. Check the latest studies of Levetiracetam.

What is Dyspnoea exacerbated?

Dyspnoea exacerbated (difficult or laboured respiration- bad situation) is found to be associated with 3,682 drugs and 1,702 conditions by eHealthMe. Check the latest studies of Dyspnoea exacerbated.

Number of reports submitted per year:

Could Levetiracetam cause Dyspnoea exacerbated in women aged 40-49?

Time on Levetiracetam when people have Dyspnoea exacerbated *

Severity of Dyspnoea exacerbated

n/a

How people recovered from Dyspnoea exacerbated

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Asthma: 20 people, 37.74%
Pneumonia: 18 people, 33.96%
Malignant Melanoma (skin cancer rises from melancytes): 18 people, 33.96%
Metastases To Central Nervous System (cancer spreads to central nervous system): 18 people, 33.96%
Constipation: 14 people, 26.42%
Pain: 9 people, 16.98%
High Blood Pressure: 5 people, 9.43%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 7.55%
Headache (pain in head): 4 people, 7.55%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 7.55%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Fatigue (feeling of tiredness): 29 people, 54.72%
Dizziness: 25 people, 47.17%
Nausea And Vomiting: 24 people, 45.28%
Nausea (feeling of having an urge to vomit): 24 people, 45.28%
Diarrhea: 24 people, 45.28%
Headache (pain in head): 23 people, 43.40%
Swallowing Difficulty: 22 people, 41.51%
Insomnia (sleeplessness): 22 people, 41.51%
Joint Pain: 22 people, 41.51%
Pain: 22 people, 41.51%

* Approximation only. Some reports may have incomplete information.

Do you take Levetiracetam and have Dyspnoea exacerbated?

- Check whether Dyspnoea exacerbated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related publications that referenced our studies:

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

Related studies:

Levetiracetam and Dyspnoea exacerbated

How the study uses the data?

The study is based on (applicable) gender, age, levetiracetam (the active ingredients of Levetiracetam) and Levetiracetam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.